domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -77,6 +77,12 @@ WHO issued conditional recommendations (not full endorsements) for GLP-1s in obe
 
 Danish cohort achieved same weight loss outcomes (16.7% at 64 weeks) using HALF the typical semaglutide dose when paired with digital behavioral support, matching clinical trial results at 50% drug cost. If this half-dose protocol proves generalizable, it could fundamentally alter the inflationary cost trajectory by reducing per-patient drug spending while maintaining efficacy.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-02-01-cms-balance-model-details-rfa-design]] | Added: 2026-03-16*
+
+BALANCE Model's dual payment mechanism (capitation adjustment + reinsurance) plus manufacturer-funded lifestyle support represents the first major policy attempt to address the chronic-use cost structure. The Medicare GLP-1 Bridge (July 2026) provides immediate price relief while full model architecture is built, indicating urgency around cost containment.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -65,6 +65,12 @@ The discontinuation problem is worse than just lost metabolic benefits - it crea
 
 Digital behavioral support may partially solve the persistence problem: UK study showed 11.53% weight loss with engagement vs 8% without at 5 months, suggesting the adherence paradox has a behavioral solution component. However, high withdrawal rates in non-engaged groups suggest this requires active participation, not passive app access.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-02-01-cms-balance-model-details-rfa-design]] | Added: 2026-03-16*
+
+BALANCE Model's manufacturer-funded lifestyle support requirement directly addresses the persistence problem by mandating evidence-based programs for GI side effects, nutrition, and physical activity—the factors most associated with discontinuation. This shifts the cost of adherence support from payers to manufacturers.
+
 ---
 
 Relevant Notes:

domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md

@@ -47,6 +47,12 @@ PACE represents the 100% risk endpoint—full capitation for all medical, social
 
 The BALANCE Model moves payment toward genuine risk by adjusting capitated rates for obesity and increasing government reinsurance for participating MA plans. This creates a direct financial incentive mechanism where plans profit from preventing obesity-related complications rather than just managing them. The model explicitly tests whether combining medication access with lifestyle supports under risk-bearing arrangements can shift the payment boundary.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-02-01-cms-balance-model-details-rfa-design]] | Added: 2026-03-16*
+
+CMS BALANCE Model demonstrates policy recognition of the VBC misalignment by implementing capitation adjustment (paying plans MORE for obesity coverage) plus reinsurance (removing tail risk) rather than expecting prevention incentives to emerge from capitation alone. This is explicit structural redesign around the identified barriers.
+
 ---
 
 Relevant Notes:

inbox/archive/.extraction-debug/2026-02-01-cms-balance-model-details-rfa-design.json

@@ -0,0 +1,32 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "cms-balance-capitation-adjustment-plus-reinsurance-removes-structural-barriers-to-glp1-coverage.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    },
+    {
+      "filename": "manufacturer-funded-lifestyle-support-shifts-behavioral-intervention-costs-from-payers-to-drugmakers.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 2,
+    "kept": 0,
+    "fixed": 2,
+    "rejected": 2,
+    "fixes_applied": [
+      "cms-balance-capitation-adjustment-plus-reinsurance-removes-structural-barriers-to-glp1-coverage.md:set_created:2026-03-16",
+      "manufacturer-funded-lifestyle-support-shifts-behavioral-intervention-costs-from-payers-to-drugmakers.md:set_created:2026-03-16"
+    ],
+    "rejections": [
+      "cms-balance-capitation-adjustment-plus-reinsurance-removes-structural-barriers-to-glp1-coverage.md:missing_attribution_extractor",
+      "manufacturer-funded-lifestyle-support-shifts-behavioral-intervention-costs-from-payers-to-drugmakers.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-16"
+}

inbox/archive/2026-02-01-cms-balance-model-details-rfa-design.md

@@ -7,9 +7,13 @@ date: 2026-01-08
 domain: health
 secondary_domains: [internet-finance]
 format: policy-document
-status: unprocessed
+status: enrichment
 priority: high
 tags: [balance-model, cms, glp-1, capitation, medicaid, medicare, value-based-care, lifestyle-support, manufacturer, adherence]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -68,3 +72,13 @@ This is CMS explicitly designing around the misalignment I identified in March 1
 PRIMARY CONNECTION: [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]
 WHY ARCHIVED: The BALANCE model's specific payment mechanism (capitation adjustment + reinsurance) is a direct policy response to the identified VBC misalignment — this design detail changes the analysis from "BALANCE is just drug coverage" to "BALANCE is structural incentive redesign"
 EXTRACTION HINT: Focus on the dual payment mechanism as the structural innovation, not the drug access expansion (which is the headline but not the analytically important insight)
+
+
+## Key Facts
+- BALANCE Model eligibility requires BMI thresholds per FDA labeling plus evidence of metabolic dysfunction (heart failure, uncontrolled hypertension, pre-diabetes)
+- Prior authorization requirements are negotiated with manufacturers, not blanket coverage
+- Manufacturers must reach 'Key Terms' agreement with CMS to become model participants
+- Medicare GLP-1 Bridge launches July 2026, earlier than full BALANCE rollout
+- Bridge provides access to manufacturer-negotiated prices before full model launches
+- State and plan participation is voluntary, creating potential adverse selection risk
+- 9.5% average body weight reduction is the manufacturer eligibility threshold